Guided Therapeutics has agreements with Konica Minolta, Inc. for the development of non-invasive esophageal cancer detection product based on its biophotonic technology platform. The company announced the completion of the clinical trial for marketing and sales approval of the Company's LuViva, positioning it to expand its early-stage commercial deployment.
Cyborg Score Rationale
The company holds a differentiated device with regulatory milestone achievement (clinical trial completion) and strategic partnerships, yet operates in a highly competitive medical device space with limited public financial visibility as an OTC-traded micro-cap with early-stage commercialization.
Top Insights
(June 2026) Made first shipment of LuViva devices, signaling commercial launch phase
(August 2025) Received $70,000 payment, indicating customer traction and revenue generation
Biophotonic technology platform positioned for multi-cancer applications beyond cervical screening
OTC-listed micro-cap structure limits access to capital and analyst coverage compared to NASDAQ/NYSE peers
Named Competitors
Cervista/ThinPrep — Cervical cancer screening and cytology platforms
Cobas HPV — HPV-based cervical cancer detection
RealTime HPV — Molecular HPV testing for cervical cancer screening
Recent Developments
(June 2026) First device shipment announcement
(August 2025) Received purchase order payment of $70,000
Clinical trial completion for LuViva regulatory approval
Open the full interactive Guided Therapeutics Inc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.